Do EBV VCA IgG antibodies appear during infection and persist for life?

EBV viral capsid antigen (VCA) IgG is a standard marker of prior EBV exposure and is expected to remain positive long term in most people after infection.

Clinical evidence

• VCA-specific IgG appears during the acute phase of EBV infection, peaks about 2–4 weeks after symptom onset, then declines modestly but usually remains detectable for life.
• Thus, a positive VCA IgG result strongly supports previous EBV infection, but does not on its own establish whether infection is acute, remote, or reactivated.
• The absolute magnitude of VCA IgG is not a validated indicator of infection timing; elevated values can persist for years.

Serologic interpretation

• Interpretation depends on the overall antibody pattern rather than VCA IgG alone:
  • VCA IgM positive with absent EBNA antibody supports recent primary infection.
  • VCA IgG plus EBNA antibody generally indicates past infection.
• EBNA antibodies are usually absent in acute infection, develop approximately 2–4 months after symptom onset, and also generally persist lifelong. Their delayed appearance helps distinguish established past infection from early primary infection.

Practical implications

• In a 74-year-old, isolated VCA IgG positivity most commonly reflects remote EBV exposure rather than a current illness, because persistent seropositivity is expected after prior infection.
• Suspected reactivation or atypical illness cannot be diagnosed from an isolated high VCA IgG result; clinical findings and, when appropriate, complementary laboratory testing are needed.

Bottom line

• The claim is well supported: EBV VCA IgG develops during infection and usually persists for life. Its main clinical meaning is evidence of prior EBV exposure, not independent proof of acute infection or reactivation.